-
2022-502122-41-00
5
2021-05-11
Clear cell renal cancer
-
2024-512844-40-00
6
2021-04-20
Infertility
-
2023-507970-42-00
5
2021-03-31
PSMA-positive metastatic hormone-sensitive prostate cancer (mHSPC)
-
2022-500439-35-00
5
2021-02-11
treatment-naive chronic lymphocytic leukemia
-
2024-514733-38-00
5
2020-11-03
Unresectable locally-advanced or metastatic HER2+ breast cancer
-
2022-502084-38-00
5
2020-10-16
Cancer
-
2024-515669-32-00
5
2020-06-30
Pulmonary arterial hypertension
-
2024-514434-20-00
5
2020-06-29
Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)
-
2024-518318-25-00
5
2020-06-24
Transthyretin Amyloidosis with Cardiomyopathy (ATTR Amyloidosis with C
-
2023-508214-42-00
5
2020-05-25
Previously treated locally advanced and unresectable or metastatic
non
-
2023-508292-37-00
5
2020-03-06
Cardiovascular Disease
-
2022-501102-35-00
5
2019-12-02
Early triple negative breast cancer
-
2023-506614-40-00
6
2019-11-11
Severe eosinophilic asthma
-
2024-510887-22-00
5
2019-09-30
Mild cognitive impairment due to Alzheimer's disease or mild Alzheimer
-
2022-502498-40-00
5
2019-07-26
myelodysplastic syndrome (MDS); beta (β)-thalassemia (THAL); myelofibr
-
2023-509087-20-00
5
2019-04-16
Metastatic Castration-resistant Prostate Cancer
-
2023-507906-15-00
5
2019-01-30
Relapsing multiple sclerosis (RMS)
-
2022-502937-24-00
5
2019-01-02
Atopic Dermatitis
-
2022-501485-22-00
5
2018-12-18
Myelodysplastic syndrome (MDS)
-
2024-515755-37-00
4
2018-07-31
Limited disease small-cell lung cancer
-
2023-508551-40-00
6
2018-06-08
Coronary artery multi-vessel disease and left main stenosis
-
2023-509976-40-00
5
2018-05-28
Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
-
2024-510913-13-00
10
2018-05-18
Previously Untreated Metastatic or Unresectable Melanoma
-
2024-517448-79-00
5
2017-11-23
Heart failure with preserved ejection fraction